Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jeannine A. Villella, Michelle K. Wilson, Neil Lorne Berinstein, Jennifer Brown, Stephanie Lheureux, Marcus O. Butler, Janelle Ramsahai, Kunle Odunsi, Mohan Karkada, John J. Nemunaitis, Michael Morse, Tanja Pejovic, James Bentley, Genevieve Weir, Lisa MacDonald, Marianne Stanford, Tomasz Burzykowski, Rita Nigam, Marc Mansour, Amit M. Oza
Institutions: Winthrop-University Hospital, Princess Margaret Cancer Centre, Ontario Institute for Cancer Research, Roswell Park Comprehensive Cancer Center, Immunovaccine (Canada), Mary Crowley Cancer Research Center, Duke Medical Center, Oregon Health & Science University, Queen Elizabeth II Health Sciences Centre, International Drug Development Institute (Belgium), University Health Network
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2598147270